Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
VTEB vs XBI: how they differ
VTEB and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Vanguard Tax-Exempt Bond Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, VTEB and XBI hold 0% of their money in the same securities at the same weight.
| Only in VTEB | Only in XBI |
|---|---|
| University of California 0.12% | Apogee Therapeutics Inc 1.49% |
| Triborough Bridge & Tunnel Authority 0.12% | Moderna Inc 1.41% |
| Colorado State Education Loan Program 0.11% | Twist Bioscience Corp 1.41% |
| State of California 0.11% | Oruka Therapeutics Inc 1.38% |
| New York City Transitional Finance Autho 0.09% | Kymera Therapeutics Inc 1.36% |
| Dallas Independent School District 0.09% | Viking Therapeutics Inc 1.31% |
| New York State Dormitory Authority 0.09% | Praxis Precision Medicines Inc 1.29% |
| Ohio Water Development Authority Water P 0.09% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| VTEB Vanguard Tax-Exempt Bond Index Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Vanguard | State Street |
| What it is | Tax-Exempt Bond | SPDR S&P Biotech |
| Total return, 1 year | +0.2% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −17.3 pts | +46.5 pts |
| Expense ratio | 0.03% | 0.35% |
| Holdings | 10185 | 150 |
VTEB in plain words
VTEB is a bond fund tracking the Tax-Exempt Bond. Over the year to Sep 11, 2026 it returned +0.2% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.03% a year. It sat 3.6% below its high of Jul 6, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VTEB or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, VTEB returned +0.2% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, VTEB or XBI?
- VTEB charges 0.03% a year and XBI charges 0.35%, so VTEB is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VTEB against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/VTEB-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources